Article
AR Splicing Variants and Resistance to AR Targeting Agents
23 May 2021
Abstract excerpt
Over the past decade, advances in prostate cancer research have led to discovery and development of novel biomarkers and effective treatments. As treatment options diversify, it is critical to further develop and use optimal biomarkers for the purpose of maximizing treatment benefit and minimizing unwanted adverse effects. Because most treatments for prostate cancer target androgen receptor (AR) signaling,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
